Dysglycemia and fluoroquinolones: are you putting patients at risk?
Catero
Martin
M
Scottsdale Healthcare Family Medicine Residency Program, Scottsdale, AZ, USA. mcatero@shc.org
D000293:Adolescent; D000328:Adult; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy; D001786:Blood Glucose / Q000187:drug effects; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D019317:Evidence-Based Medicine; D005194:Family Practice; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects* / Q000627:therapeutic use; D000077734:Gatifloxacin; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000453:epidemiology; D007003:Hypoglycemia / Q000139:chemically induced* / Q000453:epidemiology; D015994:Incidence; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D001372:Aza Compounds; D001786:Blood Glucose; D024841:Fluoroquinolones; D011804:Quinolines; D002939:Ciprofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin; D000077266:Moxifloxacin